Released Jan 29, 2013, after the close
10-K filed Jan 29, 2013, 90 days after period end · 0001354488-13-000352
Q4 2012 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income$1.08M$1.08M derived+30.6% vs Q4 2011−15.6% vs Q3 2012
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$2,630,113+22.9%
Operating Incomederived$1,373,192+33.3%
Operating Cash Flowderived$1,521,758+91.9%
Free Cash Flowderived$1,490,218+101.9%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2012dderived from reported figures | Q4 2011dderived from reported figures |
|---|---|---|
| Net Income | $1.08M | $824.43K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR